CCEL vs. LLY
Compare and contrast key facts about Cryo-Cell International, Inc. (CCEL) and Eli Lilly and Company (LLY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: CCEL or LLY.
Correlation
The correlation between CCEL and LLY is 0.48, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
CCEL vs. LLY - Performance Comparison
Key characteristics
CCEL:
-0.58
LLY:
-0.06
CCEL:
-0.58
LLY:
0.21
CCEL:
0.93
LLY:
1.03
CCEL:
-0.63
LLY:
-0.05
CCEL:
-1.56
LLY:
-0.11
CCEL:
23.80%
LLY:
12.37%
CCEL:
65.91%
LLY:
37.94%
CCEL:
-96.67%
LLY:
-68.27%
CCEL:
-56.42%
LLY:
-21.46%
Fundamentals
CCEL:
$39.43M
LLY:
$737.66B
CCEL:
$0.01
LLY:
$12.27
CCEL:
487.92
LLY:
66.95
CCEL:
0.00
LLY:
1.33
CCEL:
1.23
LLY:
15.05
CCEL:
9.72
LLY:
46.91
CCEL:
$32.10M
LLY:
$49.00B
CCEL:
$24.33M
LLY:
$40.03B
CCEL:
$3.99M
LLY:
$16.67B
Returns By Period
In the year-to-date period, CCEL achieves a -28.99% return, which is significantly lower than LLY's -2.49% return. Over the past 10 years, CCEL has underperformed LLY with an annualized return of 11.47%, while LLY has yielded a comparatively higher 28.61% annualized return.
CCEL
-28.99%
-3.32%
-34.99%
-38.02%
-2.26%
11.47%
LLY
-2.49%
3.47%
-5.45%
-2.41%
39.23%
28.61%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
CCEL vs. LLY — Risk-Adjusted Performance Rank
CCEL
LLY
CCEL vs. LLY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Cryo-Cell International, Inc. (CCEL) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
CCEL vs. LLY - Dividend Comparison
CCEL's dividend yield for the trailing twelve months is around 9.81%, more than LLY's 0.72% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CCEL Cryo-Cell International, Inc. | 9.81% | 3.37% | 0.00% | 21.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.72% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% | 2.84% |
Drawdowns
CCEL vs. LLY - Drawdown Comparison
The maximum CCEL drawdown since its inception was -96.67%, which is greater than LLY's maximum drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for CCEL and LLY. For additional features, visit the drawdowns tool.
Volatility
CCEL vs. LLY - Volatility Comparison
The current volatility for Cryo-Cell International, Inc. (CCEL) is 16.66%, while Eli Lilly and Company (LLY) has a volatility of 22.38%. This indicates that CCEL experiences smaller price fluctuations and is considered to be less risky than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
CCEL vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Cryo-Cell International, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CCEL vs. LLY - Profitability Comparison
CCEL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Cryo-Cell International, Inc. reported a gross profit of 5.98M and revenue of 7.97M. Therefore, the gross margin over that period was 75.1%.
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported a gross profit of 10.50B and revenue of 12.73B. Therefore, the gross margin over that period was 82.5%.
CCEL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Cryo-Cell International, Inc. reported an operating income of 1.06M and revenue of 7.97M, resulting in an operating margin of 13.3%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported an operating income of 5.41B and revenue of 12.73B, resulting in an operating margin of 42.5%.
CCEL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Cryo-Cell International, Inc. reported a net income of 282.86K and revenue of 7.97M, resulting in a net margin of 3.6%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported a net income of 2.76B and revenue of 12.73B, resulting in a net margin of 21.7%.